Concord Biotech Limited CC-Mar25.pdf · 2025-05-30
First of all, congratulations on a good set of numbers and consistent performance as always. So a couple of questions from my side is can you help me understand the reasons for the dip in gross margin? Is it because of a change in business mix? Or are we seeing some kind of pricing pressure on immunosuppressants with, I think, more and more competition coming in into the base? So that is my first question. And I will come back for the second question.
Okay. So as more and more formulation is built up, do we expect that the gross margin will keep on going down as the formulation keeps on going up?